Homology modeling of human Fyn kinase structure: Discovery of rosmarinic acid as a new Fyn kinase inhibitor and in Silico study of its possible binding modes

Journal of Medicinal Chemistry

Volumn 50, Issue 6, 2007, Pages 1090-1100

  Jelić, Dubravko ^a   Mildner, Boris ^a   Koštrun, Sanja ^a   Nujić, Krunoslav ^a   Verbanac, Donatella ^a   Čulić, Ognjen ^a   Antolović, Roberto ^a   Brandt, Wolfgang ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b LEIBNIZ INSTITUTE OF PLANT BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; HERBACEOUS AGENT; PROTEIN KINASE FYN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; ROSMARINIC ACID; STAUROSPORINE; T LYMPHOCYTE RECEPTOR;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; COMPUTER PROGRAM; DRUG ACTIVITY; DRUG BINDING; DRUG BINDING SITE; DRUG PROTEIN BINDING; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME STRUCTURE; HUMAN; IMMUNOCHEMISTRY; MEMBRANE TRANSPORT; METABOLIC REGULATION; NONHUMAN; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; BINDING SITES; CINNAMATES; DEPSIDES; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-FYN; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 33947659355     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0607202     Document Type: Article

References (89)

1. Mellado, M.; Rodriguez-Frade, J. M.; Manes, S.; Martinez, A. C. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu. Rev. Immunol. 2001, 19, 397-421.
2. Hanks, S. K.; Hunter, T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995, 9, 576-596.
3. Johnson, L. N.; Lewis, R. J. Structural basis for control by phosphorylation. Chem. Rev. 2001, 101, 2209-2242.
4. Milanesi, L.; Petrillo, M.; Sepe, L.; Boccia, A.; D'Agostino, N.; Passamano, M.; Di Nardo, S.; Tasco, G.; Casadio, R.; Paolella, G. Systematic analysis of human kinase genes: a large number of genes and alternative splicing events result in functional and structural diversity. BMC Bioinf. 2005, 6 (4), S20.
5. Krupa, A.; Srinivasan, N. The repertoire of protein kinases encoded in the draft version of the human genome: atypical variations and uncommon domain combinations. Genome Biol. 2002, 3 (12), 0066/ 1-14.
6. Saito, H. Histidine phosphorylation and two-component signaling in eukaryotic cells. Chem. Rev. 2001, 101, 2497-2510.
7. Hubbard, S. R.; Till, J. H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 2000, 69, 373-398.
8. Neel, B. G.; Tonks, N. K. Protein tyrosine phosphatases in signal transduction. Curr. Opin. Cell. Biol. 1997, 9, 193-204.
9. Robinson, D. R.; Wu, Y-M.; Lin, S. F. The protein tyrosine kinase family of the human genome. Oncogene 2000, 19, 5548-5557.
10. Bairoch, A. The ENZYME data bank. Nucleic Acids Res. 1993, 21 (13), 3155-3156.
11. Cooke, M. P.; Abraham, K. M.; Forbush, K. A.; Perlmutter, R. M. Regulation of T cell receptor signaling by a src family protein-tyrosine kinase (p59fyn). Cell 1991, 65 (2), 281-91.
12. Davidson, D.; Chow, L. M.; Fournel, M.; Veillette, A. Differential regulation of T cell antigen responsiveness by isoforms of the src-related tyrosine protein kinase p59fyn. J. Exp. Med. 1992, 175 (6), 1483-1492.
13. Wange, R. L.; Samelson, L. E. Complex complexes: signaling at the TCR. Immunity 1996, 5, 197-205.
14. Utting, O.; The, S. J.; The, H. S. T cells expressing receptors of different affinity for antigen ligands reveal a unique role for p59fyn in T cell development and optimal stimulation of T cells by antigen. J. Immunol. 1998, 160 (11), 5410-5419.
15. Da Silva, A. J.; Janssen, O.; Rudd, C. E. T cell receptor zeta/CD3-p59fyn(T)-associated p120/130 binds to the SH2 domain of p59fyn-(T). J. Exp. Med. 1993, 178 (6), 2107-2113.
16. fyn src Homology 4 Domain Define a Motif for Immune-Receptor Tyrosine-based Activation Motif (ITAM) Binding and for Plasma Membrane Localization. J. Cell Biol. 1996, 133 (5), 1007-1015.
17. Samelson, L. E.; Phillips, A. F.; Luong, E. T.; Klausner, R. D. Association of the fyn protein-tyrosine kinase with the T-cell antigen receptor. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 4358-4362.
18. Zhang, W.; Sloan-Lancaster, J.; Kitchen, J.; Trible, J.; Samelson, L. E. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 1998, 92, 83-92.
19. Wardenburg, J. B.; Fu, C.; Jackman, J. K.; Flotow, H.; Wilkinson, S. E.; Williams, D. H.; Johnson, R.; Kong, G.; Chan, A. C.; Findell, P. R. Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function. J. Biol. Chem. 1996, 271, 19641-19644.
20. Samelson, L. E.; Patel, M. D.; Weissman, A. M.; Harford, J. B.; Klausner, R. D. Antigen activation of murine T cells induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor. Cell 1986, 46, 1083-1090.
21. Filipp, D.; Leung, B. L.; Zhang, J.; Veillette, A.; Julius, M. Enrichment of lck in lipid rafts regulates colocalized fyn activation and the initiation of proximal signals through TCR alpha beta. J. Immunol. 2004, 172 (7), 4266-74.
22. Liang, X.; Lu, Y.; Wilkes, M.; Neubert, T. A.; Resh, M. D. The N-terminal SH4 Region of the Src Family Kinase Fyn Is Modified by Methylation and Heterogeneous Fatty Acylation. J. Biol. Chem. 2004, 279 (48), 8133-8139.
23. 2-Terminal Myristoylation and Palmitoylation at Cysteine-3. J. Cell Biol. 1997, 136 (5), 1023-1035.
24. fyn Affects Subcellular Localization. J. Biol. Chem. 1994, 269 (24), 16701-16705.
25. Horejsi, V. The roles of membrane microdomains (rafts) in T cell activation. Immunol. Rev. 2003, 191, 148-64.
26. Filipp, D.; Zhang, J.; Leung, B. L.; Shaw, A.; Levin, S. D.; Veillette, A.; Julius, M. Regulation of Fyn through translocation of activated Lck into lipid rafts. J. Exp. Med. 2003, 197 (9), 1221-7.
27. Prade, L.; Engh, R. A.; Girod, A.; Kinzel, V.; Huber, R.; Bossemeyer, D. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure 1997, 5 (12), 1627-1637.
28. Toledo, L. M.; Lydon, N. B. Structures of staurosporine bound to CDK2 and cAPK-new tools for structure-based design of protein kinase inhibitors. Structure 1997, 5 (12), 1551-1556.
29. Al-Sereiti, M. R.; Abu-Amer, K. M.; Sen, P. Pharmacology of rosemary (Rosmarinus ofticinalis Linn.) and its therapeutic potentials. Indian J. Exp. Biol. 1999, 37 (2), 124-30.
30. Iuvone, T.; De Filippis, D.; Esposito, G.; D'Amico, A.; Izzo, A. A. The Spice Sage and Its Active Ingredient Rosmarinic Acid Protect PC12 Cells from Amyloid-beta Peptide-Induced Neurotoxicity. J. Pharmacol. Exp. Ther. 2006, 317 (3), 1143-1149.
31. Lee, J.; Jung, E.; Kim, Y.; Lee, J.; Park, J.; Hong, S.; Hyun, C. G.; Park, D.; Kim, Y. S. Rosmarinic acid as a downstream inhibitor of IKK-beta in TNF-alpha-induced upregulation of CCL11 and CCR3. Br. J. Pharmacol. 2006, 148 (3), 366-375.
32. Won, J.; Hur, Y. G.; Hur, E. M.; Park, S. H.; Kang, M. A.; Choi, Y.; Park, C.; Lee, K. H.; Yun, Y. Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner. Eur. J. Immunol. 2003, 33, 870-879.
33. 2+-dependent pathways of T-cell antigen receptor-mediated signaling by inhibiting the PLC-γl and Itk activity. Blood 2003, 101 (9), 3534-3542.
34. Ahn, S. C.; Oh, W. K.; Kim, B. Y.; Kang, D. O.; Kim, M. S.; Heo, G. Y.; Ahn, J. S. Inhibitory effects of rosmarinic acid on Lck SH2 domain binding to a synthetic phosphopeptide. Planta Med. 2003, 69 (7), 642-646.
35. lck-Dependent Apoptosis in Jurkat and Peripheral T Cells via Mitochondrial Pathway Independent from Fas/Fas Ligand Interaction. J. Immunol. 2004, 172, 79-87.
36. Musacchio, A.; Saraste, M.; Wilmanns, M. High-resolution crystal structures of tyrosine kinase SH3 domains complexed with proline-rich peptides. Nat. Struct. Biol. 1994, 1, 546-551.
37. Noble, M. E.; Musacchio, A.; Saraste, M.; Courtneidge, S. A.; Wierenga, R. K. Crystal structure of the SH3 domain in human Fyn; comparison of the three-dimensional structures of SH3 domains in tyrosine kinases and spectrin. EMBO J. 1993, 12, 2617-2624.
38. Morton, C. J.; Pugh, D. J.; Brown, E. L.; Kahmann, J. D.; Renzoni, D. A.; Campbell, I. D. Solution structure and peptide binding of the SH3 domain from human Fyn. Structure 1996, 4, 705-714.
39. Renzoni, D. A.; Pugh, D. J.; Siligardi, G.; Das, P.; Morton, C. J.; Rossi, C.; Water-field, M. D.; Campbell, I. D.; Ladbury, J. E. Structural and thermodynamic characterization of the interaction of the SH3 domain from Fyn with the proline-rich binding site on the p85 subunit of PI3-kinase. Biochemistry 1996, 35, 15646-15653.
40. Arold, S.; Franken, P.; Strub, M. P.; Hoh, F.; Benichou, S.; Benarous, R.; Dumas, C. The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure 1997, 5, 1361-1372.
41. Lee, C. H.; Saksela, K.; Mirza, U. A.; Chait, B. T.; Kuriyan, J. Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell 1996, 85, 931-942.
42. Chan, B.; Lanyi, A.; Song, H. K.; Griesbach, J.; Simarro-Grande, M.; Poy, F.; Howie, D.; Sumegi, J.; Terhorst, C.; Eck, M. J. SAP couples Fyn to SLAM immune receptors. Nat. Cell Biol. 2003, 5, 155-160.
43. Rieping, W.; Habeck, M.; Nilges, M. Inferential Structure Determination. Science 2005, 309, 303-306.
44. Mulhern, T. D.; Shaw, G. L.; Morton, C. J.; Day. A. J.; Campbell, I. D. The SH2 domain from the tyrosine kinase Fyn in complex with a phosphotyrosyl peptide reveals insights into domain stability and binding specificity. Structure 1997, 5, 1313-1323.
45. Arold, S. T.; Ulmer, T. S.; Mulhern, T. D.; Werner, J. M.; Ladbury, J. E.; Campbell, I. D.; Noble, M. E. The role of the Src homology 3-Src homology 2 interface in the regulation of Src kinases. J. Biol. Chem. 2001, 276, 17199-17205.
46. Jelić, D.; Brandt, W. Three-dimensional structure of the Fyn tyrosine kinase deduced by homology modeling. Presented at the 8th Summer School on Biophysics, Rovinj, Croatia, Sep 14-26, 2003; P-105.
47. Jelić, D.; Verbanac, D.; Koštrun, S.; Brandt, W. Fyn tyrosine kinase - 3-D structure and active site determination. Presented at the 7th MipTec, Basel, Switzerland, May 3-6, 2004; P-A135.
48. Diller, D. J.; Li, R. Kinases, homology models, and high throughput docking. J. Med. Chem. 2003, 46, 4638-4647.
49. Crowther, J. R. ELISA: Theory and practice. In Methods in Molecular Biology, 1st ed.; Vol. 42, Humana Press Inc.; Totowa, NJ, 1995.
50. Anderoti, P. E.; Ludwig, G. V.; Peruski, A. H.; Tuite, J. J.; Morse, S. S.; Peruski, L. F., Jr. Immunoassay of infectious agents. BioTechniques 2003, 35 (4), 850-859.
51. Parker, G. J.; Law, T. L.; Lenoch, F. J.; Bolger, R. E. Development of High Throughput Screening Assays Using Fluorescence Polarization: Nuclear Receptor-Ligand-Binding and Kinase/Phosphatase Assays. J. Biomol. Screening 2000, 5 (2), 77-88.
52. Marangoni, A. G. Enzyme kinetics-A Modern Approach; Wiley-Interscience: New York, 2003.
53. Semba, K.; Nishizawa, M.; Miyajima, N.; Yoshida, M. C.; Sukegawa, J.; Yamanashi, Y.; Sasaki, M.; Yamamoto, T.; Toyoshima, K. Yes-related protooncogene, syn, belongs to the protein-tyrosine kinase family. Proc. Natl. Acad. Sci U.S.A. 1986, 83 (15), 5459-5463.
54. Jelić, D.; Tóth, T.; Verbanac, D. Macromolecular Databases-a background of bioinformatics. Food Technol. Biotechnol. 2003, 41 (3), 269-286.
55. National Center for Biotechnology Information [http://www.ncbi.-nlm.nih. gov].
56. Xu, W.; Doshi, A.; Lei, M.; Eck, M. J.; Harrison, S. C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 1999, 3, 629-638.
57. Williams, J. C.; Weijland, A.; Gonfloni, S.; Thompson, A.; Courtneidge, S. A.; Superti-Furga, G.; Wierenga, R. K. The 2.35 Å crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. J. Mol. Biol. 1997, 274, 757-775.
58. Schindler, T.; Sicheri, F.; Pico, A.; Gazit, A.; Levitzki, A.; Kuriyan, J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 1999, 3, 639-648.
59. Sicheri, F.; Moarefi, I.; Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997, 385, 602-609.
60. Herman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
61. Corpet, F. Multiple sequence alignment with hierarchical clustering. Nucl. Acids Res. 1988, 16 (22), 10881-10890.
62. Mittl, P. R.; Di Marco, S.; Krebs, J. F.; Bai, X.; Karanewsky, D. S.; Priestle, J. P.; Tomaselli, K. J.; Grutter, M. G. Structure of recombinant human CPP32 in complex with the tetrapeptide acetyl-Asp-Val-Ala-Asp fluoromethyl ketone. J. Biol. Chem. 1997, 272, 6539-6547.
63. ExPASy (Expert Protein Analysis System) proteomics server of the Swiss Institute of Bioinformatics [http://www.expasy.org/].
64. SYBYL. Tripos molecular modeling program package [http:// www.tripos.com/data/SYBYL].
65. Blundell, T.; Carney, D.; Gardner, S.; Hayes, F.; Howlin, B.; Hubbard, T.; Overington, J.; Singh, D. A.; Sibanda, B. L.; Sutcliffe, M. Knowledge-based protein modeling and design. Eur J. Biochem. 1988, 172 (3), 513-20.
66. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. Procheck: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
67. Sippl, M. J. Recognition of errors in three-dimensional structures of proteins. Proteins 1993, 17, 355-362.
68. Nolen, B.; Taylor, S.; Gourisankar, G. Regulation of Protein Kinases: Controlling Activity through Activation Segment Conformation. Mol. Cell 2004, 15, 661-675.
69. Zhu, X.; Kim, J. L.; Newcomb, J. R.; Rose, P. E.; Stover, D. R.; Toledo, L. M.; Zhao, H.; Morgenstern, K. A. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 1999, 7, 651-661.
70. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
71. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
72. Feng, S.; Chen, J. K.; Yu, H.; Simon, J. A.; Schreiber, S. L. Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions Science 1994, 266 (5188), 1241-1247.
73. Lamers, M. B.; Antson, A. A.; Hubbard, R. E.; Scott, R. K.; Williams, D. H. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J. Mol. Biol. 1999, 285 (2), 713-25.
74. Gadue, P.; Morton, N.; Stein, P. L. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J. Exp. Med. 1999, 190 (8), 1189-1196.
75. Denny, M. F.; Patai, B.; Straus, D. B. Differential T-Cell Antigen Receptor Signaling Mediated by the Src Family Kinases Lck and Fyn. Mol. Cell. Biol. 2000, 20 (4), 1426-1435.
76. Schillace, R. V.; Scott, J. D. Organization of kinases, phosphatases, and receptor signaling complexes. J. Clin. Invest. 1999, 103 (6), 761-765.
77. Force, T.; Kuida, K.; Namchuk, M.; Parang, K.; Kyriakis, J. M. Inhibitors of Protein Kinase Signaling Pathways: Emerging Therapies for Cardiovascular Disease. Circulation 2004, 109, 1196-1205.
78. Ho, G. J.; Drego, R.; Hakimian, E.; Masliah, E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr. Drug Targets Inflamm. Allergy 2005, 4 (2), 247-56.
79. Adcock, I. M.; Chung, K. F.; Caramori, G.; Ito, K. Kinase inhibitors and airway inflammation. Eur. J. Pharm. 2006, 533, 118-132.
80. Congreve, M.; Murray, C. W.; Blundell, T. L. Structural biology and drug discovery. Drug Discovery Today 2005, 10 (13), 895-907.
81. Hardy, L. W.; Malikayil, A. The impact of structure-guided drug design on clinical agents. Curr. Drug Discovery 2003, 12, 15-20.
82. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Could, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
83. Clark, M.; Cramer, R. D.; Van Opdenbosch, N. Validation of the General Purpose Tripos 5.2 Force Field. J. Comput. Chem. 1989, 10, 982-1012.
84. Watts, J. D.; Wilson, G. M.; Ettenhadieh, E.; Clark-Lewis, I.; Kubanek, C. A.; Astell, C. R.; Marth, J. D.; Aebersold, R. J. Purification and initial characterization of the lymphocyte-specific protein-tyrosyl kinase p561ck from a baculovirus expression system. Biol. Chem. 1992, 267 (2), 901-907.
85. Ramer, S. E.; Winkler, D. G.; Carrera, A.; Roberts, T. M.; Walsh, C. T. Purification and initial characterization of the lymphoid-cell protein-tyrosine kinase p561ck from a baculovirus expression system. Proc. Natl. Acad. Sci. U.S.A. 1991, 88 (14), 6254-6258.
86. Koegl, M.; Kypta, R. M.; Bergman, M.; Alitalo, K.; Courtneidge, S. A. Rapid and efficient purification of Src homology 2 domain-containing proteins: Fyn, Csk and phosphatidylinositol 3-kinase p85. Biochem. J. 1994, 302, 737-744.
87. Čalić, M.; Jelić, D.; Antolović, R.; Nujić, K.; Marjanović, N.; Stupin Polančec, D.; Vikić Topić, S.; Verbanac, D. Flavonoids as Inhibitors of Lck and Fyn Kinases. Croat. Chem. Acta 2005, 78 (3), 367-374.
88. Verbanac, D.; Jelić, D.; Stepanić, V.; Tatić, I.; Žiher, D.; Koštrun, S. Combined in silico and in vitro approach to drug screening. Croat. Chem. Acta 2005, 78, 133-139.
89. Bovaird, J. H.; Ngo, T. T.; Lenhoff, H. M. Optimizing the o-phenylenediamine assay for horseradish peroxidase: effects of phosphate and pH, substate and enzyme concentrations, and stopping reagents. Clin. Chem. 1982, 28 (12), 2423-2426.